Navigation Links
Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
Date:8/5/2008

r oral administration. Preclinical studies also indicate that CR845 possesses anti-itch properties. Unlike currently marketed opioids, CR845 did not inhibit intestinal transit (ileus), impair breathing, or elicit signs of addiction in animal models. CR845 and related compounds are covered by a recently issued U.S. patent.

About Cara Therapeutics

Cara Therapeutics is a privately held biotechnology company focused on developing novel, superior therapeutics to treat pain and inflammation associated with diverse medical conditions. Cara's current pipeline includes near-term clinical drug candidates within multiple classes of peripherally-acting analgesics. Cara also plans to develop entirely novel classes of analgesics that emerge from its proprietary GPCR DimerScreen(TM) technology.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements relating to the therapeutic applications of CR845 and about Cara's strategy, technologies, pre-clinical and clinical programs, and ability to identify and develop drugs, as well as other statements that are not historical facts. Actual events or results may differ materially from Cara's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Cara's research and clinical studies and Cara's ability to obtain additional financing. These forward-looking statements represent Cara's judgment as of the date of this release. Cara disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Cara Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
2. Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
3. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
4. Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
5. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
6. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
7. Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders
8. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
9. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
10. Velcura Therapeutics, Inc. Adds William Brinkerhoff to its Board of Directors
11. PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... CHENGDU, China , Aug. 28, 2014 /PRNewswire/ ... TPI ), a pharmaceutical company that specializes ... branded generics and active pharmaceutical ingredients (API) today ... the Company,s Qionglai Facility (QLF). ... Manufacturing Practice (GMP) dataset for China Food & ...
(Date:8/28/2014)... SALT LAKE CITY , Aug. 28, 2014 /PRNewswire-iReach/ ... in 2000 by service academy graduates, has published a ... its concentrated, three-day Leadership Excellence Course . In ... the  Leadership Excellence Course to Albuquerque , ... Tucson . Photo - http://photos.prnewswire.com/prnh/20140828/140814 ...
(Date:8/28/2014)... Aug. 28, 2014 Nonin Medical, Inc., the ... noninvasive medical monitoring, today announced that the Food and ... OEM/eHealth finger pulse oximeter for use in ... plugs into a telemedicine hub or kiosk through a ... in pediatric to adult patients. The Model 3231 received ...
Breaking Medicine Technology:TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2
... N.J., May 03, 2007 /PRNewswire-FirstCall/ --,Alpharma ... pharmaceutical company,through its Pharmaceuticals Division, this ... study of its investigational,abuse-deterrent, extended-release opioid ... the American Pain Society in Washington, ...
... /PRNewswire-FirstCall/ --,Genelabs Technologies, Inc. announced today that ... International Conference on Antiviral,Research being held in ... virus (HCV) polymerase inhibitor,discovered by Genelabs. , ... D. Roberts,Ph.D., Director of Medicinal Chemistry at ...
Cached Medicine Technology:Alpharma Presents Positive Pharmacokinetic Study Results of Its,Investigational Abuse-Deterrent, Extended-Release Opioid 2Alpharma Presents Positive Pharmacokinetic Study Results of Its,Investigational Abuse-Deterrent, Extended-Release Opioid 3Alpharma Presents Positive Pharmacokinetic Study Results of Its,Investigational Abuse-Deterrent, Extended-Release Opioid 4Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting 2Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting 3
(Date:8/29/2014)... August 29, 2014 RBS Reputation Management has ... Book. The service is to help those individuals and ... them on Scam Book. The service would push down the ... Scam Book complaints fully invisible on Google. , RBS ... , On being asked how company can provide guarantee of ...
(Date:8/29/2014)... August 29, 2014 A home should be a ... if unaddressed. That’s why Amica Insurance is sharing some tips to ... Council suggests taking the following safety measures: , Kitchen, ... in their original containers, and keep them away from food. ... bracket near an exit. , Bathroom , ...
(Date:8/29/2014)... has caused disease outbreaks across the Arabian Peninsula and ... has claimed the lives of several hundred people since ... have been puzzled over how easily the pathogen spreads ... led by virologists from the University of Bonn have ... the rate of human transmission is low. Still, a ...
(Date:8/29/2014)... Glendale Botox experts at Glenoaks Laser Center are ... of September. This special offer features 10 free units of ... can take advantage of this special offer to completely transform ... work with patients to determine if Botox or Juvederm is ... , Botox is a treatment made from the botulinum toxin. ...
(Date:8/29/2014)... 29, 2014 VHA Central Atlantic recognized ... in clinical care, honoring nine facilities for meeting or ... , “At Novant Health, providing quality, affordable healthcare for ... Tom Zweng, MD, executive vice president and chief medical ... a remarkable experience for each and every one of ...
Breaking Medicine News(10 mins):Health News:RBS Reputation Management Announces a New Online Reputation Management Service 2Health News:Improve Home Safety with Tips from Amica Insurance 2Health News:MERS: Low transmissibility, dangerous illness 2Health News:MERS: Low transmissibility, dangerous illness 3Health News:Glenoaks Laser Center is Now Offering a Special Promotion on Botox for the Month of September 2Health News:Novant Health Recognized for Excellence in Clinical Care 2Health News:Novant Health Recognized for Excellence in Clinical Care 3
... Million Required for Immediate Needs, NEW YORK, May ... China in a generation, news of its full impact ... trickling in at a,painfully slow speed., According to ... personnel by parachute from the air. The agency also ...
... obesity is a key culprit, study says , , WEDNESDAY, May ... in childhood, and that means preventive measures must be embraced ... Two of the biggest threats to heart health that trace ... official high blood pressure reading of 140/90 -- and obesity. ...
... May 14 AlphaMed Press, publisher of ... Oncologist, has,promoted George Kendall Vice President, Operations ... ), Ann Murphy, AlphaMed,s president, ... journals, Stem Cells and The Oncologist, and ...
... Charles (Charlie),Goldstein was honored with the first California ... at his home in Los Angeles,surrounded by family, ... passed away the following night. He was 87 ... The CDA Foundation Humanitarian Award was recently established ...
... Care, WASHINGTON, May 14 The nation,s leading,organization ... on Aging to look to assisted living providers for ... Richard Grimes, the CEO and President of the Assisted ... as it launched,hearings on the impact on Americans of ...
... Association (AVMA) declared a preliminary victory on several ... and pledging to,continue working toward the implementation of ... joint U.S. House of Representatives and,Senate conference committee, ... health that ranges from food safety protection and ...
Cached Medicine News:Health News:UNICEF Rushing Medical Supplies, Tents, Clean Water to Children Affected by Powerful Earthquake in China 2Health News:Heart Disease Starts Early in Life 2Health News:Heart Disease Starts Early in Life 3Health News:AlphaMed Press Names George Kendall Vice President, Operations and Business Development 2Health News:The California Dental Association Foundation Presents Inaugural Humanitarian Award to USC Mobile Dental Clinics Champion Charles M. Goldstein, DDS, MPH 2Health News:The California Dental Association Foundation Presents Inaugural Humanitarian Award to USC Mobile Dental Clinics Champion Charles M. Goldstein, DDS, MPH 3Health News:Assisted Living Industry Looks at Future of Alzheimer's 2Health News:AVMA Declares Preliminary Victory on Farm Bill Provisions 2
Inquire...
Flextend is a hydrocolloid skin barrier that is designed to be the most resistant to discharge and is the barrier of choice for urostomies and high output ileosotomies....
Premier pouches provide the ultimate in skin protection with our long wearing Flextend skin barriers and superior comfort with our soft and silky ComfortWear panels....
... APTT-based kit for the screening of factor-V-related ... of the test for the factor V:Q506 ... plasma with an excess of V-DEF Plasma ... to discriminate between heterozygous and homozygous factor ...
Medicine Products: